Immunotherapies, on the other hand, including agents that target PD-1/PD-L1-mediated immune evasion mechanisms, are often ineffective against most pancreatic cancers, which are frequently immunologically “cold”, infiltrated by suppressive immune cells and tumour microenvironments [10]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.